GlobeNewswire Inc.··Delveinsight30+ Pharma Companies Race to Develop CTCL Treatments as Rare Lymphoma Market Accelerates
Over 30 pharma companies are advancing 30+ pipeline drugs for cutaneous T-cell lymphoma, with market growth expected from immunotherapy adoption, though rare patient populations and high costs remain challenges.
SNGXIPHAdrug developmentpharmaceutical pipeline